Michael Freeman
Faculty Member
Last active: 2/8/2017


The Freeman laboratory focuses on two aspects of cancer drug development: 1) Development of efficacious sensitizers of ionizing radiation . 2-Indol-3-yl-methylenequinuclidin-3-ols are being used as the basis for development of novel radiation sensitizers. Defined DNA substrates, cell and animals models are used in the approach to design specific sensitizers. 2) Providing a rationale basis for development of chemoprevention agents. Expression of the genes that encode Phase II detoxification proteins is regulated by the transcription factor Nrf2,which itself is negatively regulated by association to the Cul-3 ubiquitin ligase adaptor protein Keap1. Proteomics, biochemical, biophysical and genetic approaches are used to determine if Keap1's activity is regulated by multiple Cys residues that exhibit differential chemical reactivity, allowing integration of different chemical input signals.


The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Targeting nucleophosmin 1 represents a rational strategy for radiation sensitization. Sekhar KR, Benamar M, Venkateswaran A, Sasi S, Penthala NR, Crooks PA, Hann SR, Geng L, Balusu R, Abbas T, Freeman ML (2014) Int J Radiat Oncol Biol Phys 89(5): 1106-1114
    › Primary publication · 25035215 (PubMed) · PMC4105849 (PubMed Central)
  2. Oncology scan--The concept of personalized medicine and the radiation response of tumors. Freeman ML (2014) Int J Radiat Oncol Biol Phys 88(3): 546-8
    › Primary publication · 24524335 (PubMed)
  3. Nrf1 and Nrf2 transcription factors regulate androgen receptor transactivation in prostate cancer cells. Schultz MA, Hagan SS, Datta A, Zhang Y, Freeman ML, Sikka SC, Abdel-Mageed AB, Mondal D (2014) PLoS One 9(1): e87204
    › Primary publication · 24466341 (PubMed) · PMC3899380 (PubMed Central)
  4. Thoughts on the future of research, teaching, and testing in the biological sciences of radiation oncology. Hallahan DE, Freeman ML (2014) Int J Radiat Oncol Biol Phys 88(1): 1-2
    › Primary publication · 24331646 (PubMed)
  5. Doxorubicin-mediated bone loss in breast cancer bone metastases is driven by an interplay between oxidative stress and induction of TGFβ. Rana T, Chakrabarti A, Freeman M, Biswas S (2013) PLoS One 8(10): e78043
    › Primary publication · 24205081 (PubMed) · PMC3813496 (PubMed Central)
  6. NADPH oxidase and Nrf2 regulate gastric aspiration-induced inflammation and acute lung injury. Davidson BA, Vethanayagam RR, Grimm MJ, Mullan BA, Raghavendran K, Blackwell TS, Freeman ML, Ayyasamy V, Singh KK, Sporn MB, Itagaki K, Hauser CJ, Knight PR, Segal BH (2013) J Immunol 190(4): 1714-24
    › Primary publication · 23296708 (PubMed) · PMC3563868 (PubMed Central)
  7. Loss of Nrf2 accelerates ionizing radiation-induced bone loss by upregulating RANKL. Rana T, Schultz MA, Freeman ML, Biswas S (2012) Free Radic Biol Med 53(12): 2298-307
    › Primary publication · 23085426 (PubMed) · PMC3762920 (PubMed Central)
  8. NRF2 deficiency reduces life span of mice administered thoracic irradiation. Travis EL, Rachakonda G, Zhou X, Korhonen K, Sekhar KR, Biswas S, Freeman ML (2011) Free Radic Biol Med 51(6): 1175-83
    › Primary publication · 21712086 (PubMed) · PMC3156301 (PubMed Central)
  9. Loss of NRF2 impairs gastric nitrergic stimulation and function. Mukhopadhyay S, Sekhar KR, Hale AB, Channon KM, Farrugia G, Freeman ML, Gangula PR (2011) Free Radic Biol Med 51(3): 619-25
    › Primary publication · 21605664 (PubMed) · PMC3129370 (PubMed Central)